Blake Borgeson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Blake Borgeson is Director of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 7.07 Million shares of RXRX, which is worth approximately $40.3 Million. The most recent transaction as insider was on Feb 07, 2023, when has been sold 8,885 shares (Class A Common Stock) at a price of $8.81 per share, resulting in proceeds of $78,276. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 7.07M

0.93% 3M change

4.61% 12M change

Total Value Held $40.3 Million

Blake Borgeson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 07 2023	SELL Open market or private sale	$78,276 $8.81 p/Share	8,885 Reduced 0.12%	7,602,942 Class A Common Stock
Jan 24 2023	SELL Open market or private sale	$77,388 $8.71 p/Share	8,885 Reduced 0.12%	7,611,827 Class A Common Stock
Jan 10 2023	SELL Open market or private sale	$68,325 $7.69 p/Share	8,885 Reduced 0.12%	7,620,712 Class A Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	1,325 Added 0.02%	7,629,597 Class A Common Stock
Dec 27 2022	SELL Open market or private sale	$64,416 $7.25 p/Share	8,885 Reduced 0.12%	7,628,272 Class A Common Stock
Dec 13 2022	SELL Open market or private sale	$79,609 $8.96 p/Share	8,885 Reduced 0.12%	7,637,157 Class A Common Stock
Nov 29 2022	SELL Open market or private sale	$77,743 $8.75 p/Share	8,885 Reduced 0.12%	7,646,042 Class A Common Stock
Nov 16 2022	SELL Open market or private sale	$197,602 $11.12 p/Share	17,770 Reduced 0.23%	7,654,927 Class A Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	-	920 Added 0.01%	7,672,697 Class A Common Stock
Jul 01 2022	BUY Grant, award, or other acquisition	-	1,186 Added 0.02%	7,671,777 Class A Common Stock
Jun 14 2022	BUY Grant, award, or other acquisition	-	18,145 Added 0.24%	7,670,591 Class A Common Stock
Apr 01 2022	BUY Grant, award, or other acquisition	-	1,300 Added 0.02%	7,652,446 Class A Common Stock
Jan 04 2022	SELL Open market or private sale	$173,539 $18.03 p/Share	9,625 Reduced 0.13%	7,651,146 Class A Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	555 Added 0.01%	7,660,771 Class A Common Stock
Dec 21 2021	SELL Open market or private sale	$180,469 $18.75 p/Share	9,625 Reduced 0.13%	7,660,216 Class A Common Stock
Dec 07 2021	SELL Open market or private sale	$196,350 $20.4 p/Share	9,625 Reduced 0.13%	7,669,841 Class A Common Stock
Nov 18 2021	SELL Open market or private sale	$179,795 $18.68 p/Share	9,625 Reduced 0.13%	7,679,466 Class A Common Stock
Oct 01 2021	BUY Grant, award, or other acquisition	-	457 Added 0.01%	7,689,091 Class A Common Stock
Jul 01 2021	BUY Grant, award, or other acquisition	-	278 Added 0.0%	7,688,634 Class A Common Stock
Apr 20 2021	SELL Conversion of derivative security	-	7,688,356 Reduced 100.0%	0 Common Stock
Apr 20 2021	BUY Conversion of derivative security	-	923,052 Added 10.72%	7,688,356 Common Stock
Apr 20 2021	BUY Conversion of derivative security	-	7,688,356 Added 50.0%	7,688,356 Class A Common Stock
Apr 16 2021	BUY Grant, award, or other acquisition	-	6,250 Added 0.09%	6,765,304 Common Stock

Blake Borgeson

Director

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account